News

Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business update on Thursday, August 6

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the markets

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2020, highlighting revenue growth and financial strength as well as the advancement of the company’s clinical

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2020 financial results after the market

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, has enhanced its crisis forecasting and planning technology to predict the COVID-19 census for any U.S. hospital on a given

Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, and Heal, a market leader in transforming healthcare through in-home, comprehensive primary care, today

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2020.

For the second quarter of 2020, worldwide sales

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will

Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2020 fourth quarter and full year on Tuesday, August 25, 2020, at approximately 6:30 a.m. EDT. The

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2020.

Second Quarter 2020 Financial Highlights:

• 
  Revenue grew 34% versus the same

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2020.

Second Quarter 2020 Financial Highlights:

• 
  Revenue grew 34% versus the same

Novocure (NASDAQ:NVCR) announced today the recipients of the AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a joint effort between Novocure and the American

Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2020, increased its 2020 financial guidance for revenues and Adjusted diluted EPS⁽³⁾ and reaffirmed all other components of its

Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2020, increased its 2020 financial guidance for revenues and Adjusted diluted EPS⁽³⁾ and reaffirmed all other components of its

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified

Agilent Technologies Inc. (NYSE: A) will release third-quarter fiscal year 2020 financial results after the stock market closes on Aug. 18. The company will also host a live webcast of its investor

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that data from the cervical cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the safety and

Lysogene (Paris:LYS)(FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, provides H1 2020 Business update.

As of 30 June 2020, cash and

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 6, 2020, following the release of its second